wire - news in brief
Category
Results 201 - 250 of 391.
GTX medical, an EPFL spin-off that has developed an implantable neuromodulation therapy to help people with spinal cord injuries walk again, merged today with NeuroRecovery Technologies, a US-based company, developing a transcutaneous stimulation therapy to improve upper limb function after a SCI.
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer Data will be submitted to
As part of its 50th anniversary celebration, EPFL is highlighting his commitment for open and reproducible research through an exceptional Open Science Day, today.
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
A number of researchers have published critical comments about an ETH Zurich study that generated a lot of interest with its quantitative assessment of the technical potential that reforestation holds for reducing CO2. In the following interview, Professor Detlef Günther, Vice President for Research and Corporate Relations, explains why he welcomes this discourse.
Gerd Folkers was the first head of Critical Thinking ETH (CTETH) and left an indelible mark on the initiative.
Only one out of a hundred houses per year are renovated to make them more energy efficient - less than half the number needed to achieve the goals of the Energy Strategy 2050 for buildings. The National Research Programme "Energy" shows that the necessary technologies are available, but there is a lack of appropriate planning, building and energy laws, as well as of expertise.
ETH scores highly on interdisciplinarity
Two ETH Zurich projects and one with ETH involvement have been awarded one of the coveted ERC Synergy Grants. These EU grants offer up to EUR 14 million to promote interdisciplinary collaboration on research projects. Correlations and questions in research are becoming more and more complex, which makes collabo-ration between researchers from different fields necessary.
Two ETH Zurich projects and one with ETH involvement have been awarded one of the coveted ERC Synergy Grants. These EU grants offer up to EUR 14 million to promote interdisciplinary collaboration on research projects. Correlations and questions in research are becoming more and more complex, which makes collabo-ration between researchers from different fields necessary.
Two students from EPFL have developed a smart speaker with voice-activation technology that connects patients directly to their loved ones as well as caregivers and emergency services.
Romain Fleury, a tenure-track assistant professor who heads the Laboratory of Wave Engineering, has been named best teacher in electrical and electronic engineering.
Three researchers share this year's Nobel Prize in Chemistry. They are being honoured for their respective contributions in research that led to today's rechargeable lithium-ion batteries - and has made our smartphones and electric cars possible in their current form.
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of pat
40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of pat
ETH spinoff FenX transforms industrial waste into a porous foam suitable for building insulation. Unlike other sustainable materials used for the purpose, this type of insulation is non-flammable and inexpensive to produce.
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.
ERC Synergy Grant for viral infection and cellular regulation research
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.
An aerodynamic bike that was designed using software from Neural Concept, a spin-off from the Computer Vision Laboratory (CVLab) in the EPFL School of Computer and Communication Sciences, has broken two world records for cycling speed.
Details of Dental Wear Revealed
The teeth of mammals experience constant wear. However, the details of these wear processes are largely unknown. Researchers at the University of Zurich have now demonstrated that the various areas of herbivores' teeth differ in how susceptible they are to dental wear, detailing an exact chronology.
The teeth of mammals experience constant wear. However, the details of these wear processes are largely unknown. Researchers at the University of Zurich have now demonstrated that the various areas of herbivores' teeth differ in how susceptible they are to dental wear, detailing an exact chronology.
"I regard myself as a descendent of the true Modernists," a young Rem Koolhaas told Dutch journal wonen-TA/BK in 1978.
Prostate cancer research, important SNF grant goes to the IOR
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Universitŕ della Svizzera italiana), has received a 4-year grant
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Universitŕ della Svizzera italiana), has received a 4-year grant
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
Whether mobile phone or automatic toilets - electronic devices are becoming increasingly complex. And who hasn't heard stories of devices that fail precisely after the warranty has expired?
Self-driving cars, the automatic detection of cancer cells, online translation: deep learning makes it all possible. The ETH spin-off Mirage Technologies has developed a deep learning platform that aims to help start-ups and companies more quickly develop and optimise their products. The name has a fairytale feel to it, with its reference to mirages and the suggestion of illusion.
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Taking sustainability into space
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
These days, Microsoft officially opens a lab in Zurich dedicated to researching mixed reality technologies and artificial intelligence.
Marc Angélil played a decisive role in shaping the teaching of architecture at ETH Zurich, both as professor and as temporary head of the department.
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
